 Cyclerion Therapeutics, Inc. CYCN, a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase sGC stimulators for the treatment of serious and orphan diseases, today announced that it recently closed enrollment for both of its ongoing clinical studies. The Company also provided additional corporate updates. 